NO20022925L - EP4 reseptor selektive agonister for behandling av osteoporose - Google Patents
EP4 reseptor selektive agonister for behandling av osteoporoseInfo
- Publication number
- NO20022925L NO20022925L NO20022925A NO20022925A NO20022925L NO 20022925 L NO20022925 L NO 20022925L NO 20022925 A NO20022925 A NO 20022925A NO 20022925 A NO20022925 A NO 20022925A NO 20022925 L NO20022925 L NO 20022925L
- Authority
- NO
- Norway
- Prior art keywords
- osteoporosis
- treatment
- selective agonists
- receptor selective
- receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17135399P | 1999-12-22 | 1999-12-22 | |
| PCT/IB2000/001711 WO2001046140A1 (en) | 1999-12-22 | 2000-11-20 | Ep4 receptor selective agonists in the treatment of osteoporosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20022925D0 NO20022925D0 (no) | 2002-06-18 |
| NO20022925L true NO20022925L (no) | 2002-06-18 |
Family
ID=22623430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20022925A NO20022925L (no) | 1999-12-22 | 2002-06-18 | EP4 reseptor selektive agonister for behandling av osteoporose |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US6737437B2 (no) |
| EP (1) | EP1110949B1 (no) |
| JP (1) | JP2001181210A (no) |
| KR (1) | KR100419681B1 (no) |
| CN (1) | CN1413190A (no) |
| AP (2) | AP2002002555A0 (no) |
| AT (1) | ATE250575T1 (no) |
| AU (2) | AU1293101A (no) |
| BG (1) | BG106882A (no) |
| BR (1) | BR0016560A (no) |
| CA (1) | CA2329678A1 (no) |
| CO (1) | CO5251453A1 (no) |
| CR (1) | CR6678A (no) |
| CZ (1) | CZ20022048A3 (no) |
| DE (1) | DE60005471T2 (no) |
| DK (1) | DK1110949T3 (no) |
| EA (1) | EA005293B1 (no) |
| EE (1) | EE200200355A (no) |
| ES (1) | ES2204458T3 (no) |
| GE (1) | GEP20043203B (no) |
| HR (1) | HRP20020537A2 (no) |
| HU (1) | HUP0005001A3 (no) |
| IL (1) | IL140325A0 (no) |
| IS (1) | IS6388A (no) |
| MA (1) | MA26852A1 (no) |
| MX (1) | MXPA02006322A (no) |
| NO (1) | NO20022925L (no) |
| OA (1) | OA12117A (no) |
| PE (1) | PE20010953A1 (no) |
| PL (1) | PL356662A1 (no) |
| PT (1) | PT1110949E (no) |
| SK (1) | SK8552002A3 (no) |
| TR (2) | TR200201643T2 (no) |
| UA (1) | UA72293C2 (no) |
| WO (1) | WO2001046140A1 (no) |
| ZA (1) | ZA200007694B (no) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010056060A1 (en) * | 2000-02-07 | 2001-12-27 | Cameron Kimberly O. | Treatment of osteoporsis with EP2/EP4 receptor selective agonists |
| EP1339678B1 (en) * | 2000-11-27 | 2007-09-26 | Pfizer Products Inc. | Ep4 receptor selective agonists in the treatment of osteoporosis |
| MXPA04000456A (es) * | 2001-07-16 | 2004-03-18 | Hoffmann La Roche | Analogos de prostaglandina como agonistas del receptor ep4. |
| DK1408961T3 (da) | 2001-07-16 | 2007-11-05 | Hoffmann La Roche | 2 pyrrolidon-derivater som prostanoide agonister |
| MXPA04000757A (es) | 2001-07-23 | 2004-07-08 | Ono Pharmaceutical Co | Remedios para enfermedades con perdida de masa de hueso que tienen agonistas ep4 como ingrediente activo. |
| CN1893977B (zh) * | 2001-07-23 | 2012-12-05 | 小野药品工业株式会社 | 以ep4激动剂为活性成分的治疗与骨质损失有关的疾病的药物 |
| KR20050012221A (ko) * | 2001-11-12 | 2005-01-31 | 오노 야꾸힝 고교 가부시키가이샤 | 프로스타글란딘 유도체를 유효성분으로 하는 국소 투여용지속성 필름형 제제 |
| US20040204590A1 (en) * | 2001-12-03 | 2004-10-14 | Ogidigben Miller J. | Ep4 receptor agonist, compositions and methods thereof |
| US20040254230A1 (en) * | 2001-12-03 | 2004-12-16 | Ogidigben Miller J. | Method for treating ocular hypertension |
| AU2002358772B2 (en) | 2001-12-20 | 2008-11-20 | Merck Serono Sa | Pyrrolidine derivatives as prostaglandin modulators |
| TW200305425A (en) | 2002-03-05 | 2003-11-01 | Ono Pharmaceutical Co | 8-Azaprostaglandin derivatives and medicament containing same as active ingredient |
| CA2479222A1 (en) * | 2002-03-18 | 2003-09-25 | Pfizer Products Inc. | Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension |
| US6573294B1 (en) * | 2002-05-14 | 2003-06-03 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
| AU2011202937B2 (en) * | 2002-05-14 | 2012-06-07 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
| ATE487514T1 (de) | 2002-06-06 | 2010-11-15 | Merck Frosst Canada Ltd | 1,5-disubstituierte pyrrolid-2-on-derivate zur verwendung als ep4 rezeptor agonisten zur behandlung von augenkrankheiten wie z.b. glaukom |
| US7419999B2 (en) | 2002-06-10 | 2008-09-02 | Applied Research Systems Ars Holding N.V. | Gamma lactams as prostaglandin agonists and use thereof |
| WO2004032965A1 (ja) | 2002-10-10 | 2004-04-22 | Ono Pharmaceutical Co., Ltd. | 内因性修復因子産生促進剤 |
| US7196082B2 (en) | 2002-11-08 | 2007-03-27 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
| JP2006510742A (ja) | 2002-11-08 | 2006-03-30 | メルク エンド カムパニー インコーポレーテッド | 高眼圧治療用眼科組成物 |
| US7053085B2 (en) | 2003-03-26 | 2006-05-30 | Merck & Co. Inc. | EP4 receptor agonist, compositions and methods thereof |
| CA2511255C (en) * | 2003-01-10 | 2009-04-07 | F. Hoffmann-La Roche Ag | 2-piperidone derivatives as prostaglandin agonists |
| EP1586564B1 (en) * | 2003-01-21 | 2012-11-28 | Ono Pharmaceutical Co., Ltd. | 8-azaprostaglandin derivatives and medicinal uses thereof |
| CA2513652A1 (en) | 2003-03-03 | 2004-09-16 | Applied Research Systems Ars Holding N.V. | G-lactam derivatives as prostaglandin agonists |
| US6734206B1 (en) * | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure |
| US6734201B1 (en) * | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents |
| US7179820B2 (en) | 2003-06-06 | 2007-02-20 | Allergan, Inc. | Piperidinyl prostaglandin E analogs |
| JP2006528154A (ja) | 2003-07-18 | 2006-12-14 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | プロスタグランジン受容体のモジュレータとしてのヒドラジド誘導体 |
| JP2007504228A (ja) | 2003-09-02 | 2007-03-01 | メルク エンド カムパニー インコーポレーテッド | 高眼圧症を治療するための眼組成物 |
| JP2007504236A (ja) | 2003-09-04 | 2007-03-01 | メルク エンド カムパニー インコーポレーテッド | 高眼圧症を治療するための眼用組成物 |
| CA2537410C (en) | 2003-09-04 | 2009-08-11 | Merck & Co., Inc. | Ophthalmic indazole comprising compositions for treating ocular hypertension |
| WO2005027931A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist |
| WO2005080367A1 (en) | 2004-02-12 | 2005-09-01 | Pharmagene Laboratories Limited | Ep2 receptor agonists |
| CN1988903A (zh) | 2004-07-20 | 2007-06-27 | 默克公司 | 用于治疗高眼压症的眼用组合物 |
| EP1824819B1 (en) | 2004-12-06 | 2010-01-20 | Merck Serono SA | Pyrrolidin-2-one derivatives for use as dp1 receptor agonists |
| US7531533B2 (en) | 2005-01-27 | 2009-05-12 | Asahi Kasei Pharma Corporation | 6-Membered heterocyclic compound and use thereof |
| EP1878429B1 (en) | 2005-04-28 | 2011-08-03 | Ono Pharmaceutical Co., Ltd. | Trenadermal absorption preparation |
| KR100686186B1 (ko) * | 2005-06-13 | 2007-02-26 | 영진종합건설 주식회사 | 교량용 배수 구조물 |
| CA2618486A1 (en) | 2005-08-09 | 2007-02-15 | Asterand Uk Limited | Ep2 receptor agonists |
| US8410171B2 (en) | 2006-10-26 | 2013-04-02 | Ono Pharmaceutical Co., Ltd. | Adhesive preparation |
| US9394520B2 (en) | 2006-12-08 | 2016-07-19 | University Of Rochester | Expansion of hematopoietic stem cells |
| US20090124695A1 (en) | 2007-11-14 | 2009-05-14 | Cayman Chemical Company | Prostaglandin e1 and e2 analogs for the treatment of various medical conditions |
| CA2738045C (en) | 2010-05-28 | 2019-02-19 | Simon Fraser University | Conjugate compounds, methods of making same, and uses thereof |
| AU2012290987B2 (en) | 2011-08-02 | 2017-04-20 | Ono Pharmaceutical Co., Ltd. | Left ventricular diastolic function improving agent |
| CN104640542B (zh) | 2012-07-19 | 2017-09-22 | 开曼化学股份有限公司 | 用于ep4介导的骨相关疾病和病症的二氟内酰胺组合物 |
| EP2913047B1 (en) | 2012-10-29 | 2019-05-08 | Cardio Incorporated | Pulmonary disease-specific therapeutic agent |
| CN105143217A (zh) * | 2013-03-15 | 2015-12-09 | 开曼化学股份有限公司 | 作为ep4受体选择性激动剂的内酰胺化合物用于治疗ep4介导的疾病和病症 |
| WO2014144610A1 (en) | 2013-03-15 | 2014-09-18 | Cayman Chemical Company, Inc. | Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions |
| US10729810B2 (en) | 2013-07-19 | 2020-08-04 | Cayman Chemical Company, Inc | Methods, systems, and compositions for promoting bone growth |
| CA2920856A1 (en) | 2013-08-09 | 2015-02-12 | Ardelyx, Inc. | Ph modulating compounds for inhibiting gastrointestinal phosphate uptake |
| WO2015056504A1 (ja) | 2013-10-15 | 2015-04-23 | 小野薬品工業株式会社 | 薬剤溶出性ステントグラフト |
| CN107849072B (zh) | 2015-06-12 | 2020-12-15 | 西蒙弗雷泽大学 | 酰胺连接的ep4激动剂-二膦酸盐化合物及其用途 |
| JP2022533251A (ja) | 2019-05-21 | 2022-07-21 | アルデリックス， インコーポレイテッド | 患者において血清リン酸塩を低下させるための組み合わせ |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR897566A (fr) | 1942-08-28 | 1945-03-26 | Bopp & Reuther Gmbh | Machine à rotors |
| US3528961A (en) | 1966-08-16 | 1970-09-15 | Allied Chem | Monoazo dyes from e-caprolactam |
| US3780095A (en) | 1970-04-08 | 1973-12-18 | Byk Gulden Lomberg Chem Fab | Acylated anilino-carboxylic acids and their salts |
| US3987091A (en) | 1973-04-12 | 1976-10-19 | Merck & Co., Inc. | 11,12-secoprostaglandins |
| US4033996A (en) | 1973-04-25 | 1977-07-05 | Merck & Co., Inc. | 8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins |
| SE7414770L (no) | 1973-12-13 | 1975-06-16 | Merck & Co Inc | |
| DK366475A (da) | 1974-08-30 | 1976-03-01 | Merck & Co Inc | Fremgangsmade til fremstilling af aryloxy- eller arylthioholdige secoprostaglandiner |
| US4055596A (en) | 1974-09-13 | 1977-10-25 | Merck & Co., Inc. | 11,12-Seco-prostaglandins |
| US3991106A (en) | 1974-09-13 | 1976-11-09 | Merck & Co., Inc. | 16-Ethers of 8-aza-9-dioxothia-11,12-seco-prostaglandins |
| US4113873A (en) | 1975-04-26 | 1978-09-12 | Tanabe Seiyaku Co. Ltd. | 8-azaprostanoic acid derivatives |
| DE2528664A1 (de) | 1975-06-27 | 1977-01-13 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
| IL49325A (en) | 1976-03-31 | 1979-11-30 | Labaz | 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them |
| DE2619638A1 (de) | 1976-05-04 | 1977-11-17 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
| US4177346A (en) | 1976-08-06 | 1979-12-04 | Pfizer Inc. | 1,5-Disubstituted-2-pyrrolidones |
| US4175203A (en) | 1976-12-17 | 1979-11-20 | Merck & Co., Inc. | Interphenylene 11,12-secoprostaglandins |
| US4243678A (en) | 1977-12-30 | 1981-01-06 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Acylhydrocarbylaminoalkanoic acids, compositions and uses |
| DE3000377A1 (de) | 1980-01-07 | 1981-07-09 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel |
| DE3042482A1 (de) | 1980-11-11 | 1982-06-24 | A. Nattermann & Cie GmbH, 5000 Köln | N-benzoyl- (omega) -anilinoalkancarbonsaeuren, -salze und -ester, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
| EP0068968B1 (fr) | 1981-06-16 | 1985-09-18 | Choay S.A. | Nouveaux médicaments contenant à titre de substance active des composés du type arylbenzènesulfonamide et leurs procédés de préparation |
| AU6427596A (en) * | 1992-04-14 | 1996-10-31 | Alfred Maximillian Stessl | A boat hull |
| TW383306B (en) | 1992-12-22 | 2000-03-01 | Lilly Co Eli | New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol |
| NZ335770A (en) * | 1996-12-20 | 2005-01-28 | Pfizer | Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 agonists such as tetrazolyl or carboxylic acid derivatives |
| GB2330307A (en) * | 1998-02-07 | 1999-04-21 | Glaxo Group Ltd | EP4 Receptor antagonists as bone resorption inhibitors |
| EP1148877A4 (en) * | 1998-10-15 | 2003-01-22 | Merck & Co Inc | METHOD FOR INHIBITING BONE RESORPTION |
| JP2002527400A (ja) * | 1998-10-15 | 2002-08-27 | メルク エンド カムパニー インコーポレーテッド | 骨形成刺激方法 |
-
2000
- 2000-11-20 BR BR0016560-3A patent/BR0016560A/pt not_active IP Right Cessation
- 2000-11-20 CZ CZ20022048A patent/CZ20022048A3/cs unknown
- 2000-11-20 GE GEAP20006502A patent/GEP20043203B/en unknown
- 2000-11-20 SK SK855-2002A patent/SK8552002A3/sk unknown
- 2000-11-20 MX MXPA02006322A patent/MXPA02006322A/es active IP Right Grant
- 2000-11-20 TR TR2002/01643T patent/TR200201643T2/xx unknown
- 2000-11-20 PL PL00356662A patent/PL356662A1/xx not_active Application Discontinuation
- 2000-11-20 AU AU12931/01A patent/AU1293101A/en not_active Abandoned
- 2000-11-20 WO PCT/IB2000/001711 patent/WO2001046140A1/en active Application Filing
- 2000-11-20 CN CN00817566A patent/CN1413190A/zh active Pending
- 2000-11-20 EA EA200200505A patent/EA005293B1/ru not_active IP Right Cessation
- 2000-11-20 AP APAP/P/2002/002555A patent/AP2002002555A0/en unknown
- 2000-11-20 EE EEP200200355A patent/EE200200355A/xx unknown
- 2000-11-20 OA OA1200200177A patent/OA12117A/en unknown
- 2000-11-20 UA UA2002065186A patent/UA72293C2/uk unknown
- 2000-11-20 AP APAP/P/2001/002357A patent/AP2001002357A0/en unknown
- 2000-12-11 TR TR2003/01841T patent/TR200301841T4/xx unknown
- 2000-12-11 ES ES00311034T patent/ES2204458T3/es not_active Expired - Lifetime
- 2000-12-11 DK DK00311034T patent/DK1110949T3/da active
- 2000-12-11 PT PT00311034T patent/PT1110949E/pt unknown
- 2000-12-11 AT AT00311034T patent/ATE250575T1/de not_active IP Right Cessation
- 2000-12-11 DE DE60005471T patent/DE60005471T2/de not_active Expired - Fee Related
- 2000-12-11 EP EP00311034A patent/EP1110949B1/en not_active Expired - Lifetime
- 2000-12-14 IL IL14032500A patent/IL140325A0/xx unknown
- 2000-12-15 US US09/738,670 patent/US6737437B2/en not_active Expired - Fee Related
- 2000-12-19 PE PE2000001368A patent/PE20010953A1/es not_active Application Discontinuation
- 2000-12-19 KR KR10-2000-0078214A patent/KR100419681B1/ko not_active IP Right Cessation
- 2000-12-20 CA CA002329678A patent/CA2329678A1/en not_active Abandoned
- 2000-12-20 AU AU72393/00A patent/AU763983B2/en not_active Ceased
- 2000-12-20 ZA ZA200007694A patent/ZA200007694B/xx unknown
- 2000-12-21 HU HU0005001A patent/HUP0005001A3/hu unknown
- 2000-12-22 CO CO00097391A patent/CO5251453A1/es not_active Application Discontinuation
- 2000-12-22 JP JP2000390594A patent/JP2001181210A/ja not_active Ceased
-
2001
- 2001-11-16 US US09/991,585 patent/US6642266B2/en not_active Expired - Fee Related
-
2002
- 2002-05-17 IS IS6388A patent/IS6388A/is unknown
- 2002-06-12 CR CR6678A patent/CR6678A/es not_active Application Discontinuation
- 2002-06-13 MA MA26686A patent/MA26852A1/fr unknown
- 2002-06-18 NO NO20022925A patent/NO20022925L/no not_active Application Discontinuation
- 2002-06-20 HR HRP20020537 patent/HRP20020537A2/hr not_active Application Discontinuation
- 2002-06-28 BG BG106882A patent/BG106882A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20022925L (no) | EP4 reseptor selektive agonister for behandling av osteoporose | |
| NO20032360D0 (no) | EP4 reseptor selektive agonister for behandling av osteoporose | |
| NO20022105D0 (no) | Positive modulatorer av nikotinreseptoragonister | |
| PT1189916E (pt) | N-pirazole agonistas do receptor a2a | |
| NO20014379D0 (no) | Anvendelse av Xenon for behandling av Neurointoksikasjoner | |
| IS6785A (is) | EP4 viðtakahindrar til meðhöndlunar á liðagigt | |
| NO20013380L (no) | 2-aminobenzoksazinonderivater for behandling av fedme | |
| NO20034122L (no) | Sammensmeltede pyridinderivater for anvendelse som vanilloidreseptorantagonister for behandling av smerte | |
| NO20013369D0 (no) | Arylpiperazinyl-cykloheksyl-indol-derivater for behandling av depresjon | |
| NO20016246L (no) | Selektiv iGluR5 reseptorantagonist for behandling av migrene | |
| NO20013381D0 (no) | 2-oksybenzoksazinonderivater for behandling av fedme | |
| NO20020574D0 (no) | Substituerte 1,5-dihydropyrrol-2-onderivater som er virksomme som NMDA-reseptorantagonister for behandlingen av smertetilstanden | |
| NO20022009D0 (no) | Positive modulatorer av nikotiniske reseptoragonister | |
| EP1121939A3 (en) | Treatment of osteoporosis with EP2/EP4 receptor selective agonists | |
| DE60028368D1 (de) | Agonisten des peroxisom aktivator-responsiven rezeptors | |
| HK1059782A1 (en) | Indole derivatives useful for the treatment of cnsdisorders | |
| NO20022142L (no) | Anvendelse av dopamin-D3 reseptor agonister for behandling av saltavhengig hypertensjon | |
| FI5227U1 (fi) | Laitteisto laastin jakelemiseksi | |
| DK1200402T3 (da) | Substituerede 1,5-dihydropyrrol-2-on-derivater med virkning som NMDA-receptorantagonister til behandling af smertetilstande |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |